Literature DB >> 20093228

Comparison of fluorescence in situ hybridization, p57 immunostaining, flow cytometry, and digital image analysis for diagnosing molar and nonmolar products of conception.

Benjamin R Kipp1, Rhett P Ketterling, Trynda N Oberg, Margot A Cousin, Amy M Plagge, Anne E Wiktor, Johnita M Ihrke, Cecelia H Meyers, William G Morice, Kevin C Halling, Amy C Clayton.   

Abstract

Pathologic examination of products of conception (POC) is used to differentiate hydropic abortus (HA), partial hydatidiform mole (PM), and complete hydatidiform mole (CM). Histologic classification of POC specimens can be difficult, and ancillary testing is often required for a definitive diagnosis. This study evaluated 66 POC specimens by flow cytometry, digital image analysis, p57 immunohistochemical analysis, and fluorescence in situ hybridization (FISH). The final diagnosis, based on the combined analysis of all test results, included 33 HAs, 24 PMs, and 9 CMs. The p57 immunostain identified 9 CMs that were evaluated as nontriploid by all other techniques. FISH seems to have the best accuracy (100%) for determining whether a specimen contains a triploid chromosome complement. These data suggest that the combination of p57 and FISH seems to be the best ancillary testing strategy to aid pathologists in the appropriate identification of CM, PM, and HA in POC specimens.

Mesh:

Substances:

Year:  2010        PMID: 20093228     DOI: 10.1309/AJCPV7BRDUCX0WAQ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  8 in total

1.  The role of morphology in combination with ploidy analysis in characterizing early gestational abortion.

Authors:  Isabella Grinschgl; Sebastian Mannweiler; Margit Holzapfel-Bauer; Ulrich Pferschy; Gerald Hoefler; Barbara Guertl
Journal:  Virchows Arch       Date:  2012-12-21       Impact factor: 4.064

2.  Diagnostic reproducibility of hydatidiform moles: ancillary techniques (p57 immunohistochemistry and molecular genotyping) improve morphologic diagnosis.

Authors:  Russell Vang; Mamta Gupta; Lee-Shu-Fune Wu; Anna V Yemelyanova; Robert J Kurman; Kathleen M Murphy; Cheryl Descipio; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2012-03       Impact factor: 6.394

3.  Diagnostic reproducibility of hydatidiform moles: ancillary techniques (p57 immunohistochemistry and molecular genotyping) improve morphologic diagnosis for both recently trained and experienced gynecologic pathologists.

Authors:  Mamta Gupta; Russell Vang; Anna V Yemelyanova; Robert J Kurman; Fanghong Rose Li; Emily C Maambo; Kathleen M Murphy; Cheryl DeScipio; Carol B Thompson; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2012-12       Impact factor: 6.394

4.  Utility of p57 immunohistochemistry in differentiating between complete mole, partial mole & non-molar or hydropic abortus.

Authors:  Abhimanyu Samadder; Rakhee Kar
Journal:  Indian J Med Res       Date:  2017-01       Impact factor: 2.375

5.  Variable Number Tandem Repeat (VNTR) Genotyping of Hydatidiform Mole in Iranian Patients.

Authors:  Zahra Pakzad; Hossein Mozdarani; Narges Izadi-Mood; Shirin Niromanesh
Journal:  Avicenna J Med Biotechnol       Date:  2014-10

6.  Single nucleotide polymorphism-based microarray analysis for the diagnosis of hydatidiform moles.

Authors:  Yingjun Xie; Xiaojuan Pei; Yu Dong; Huiqun Wu; Jianzhu Wu; Huijuan Shi; Xuying Zhuang; Xiaofang Sun; Jialing He
Journal:  Mol Med Rep       Date:  2016-05-05       Impact factor: 2.952

7.  Molecular and Immunohistochemical Characteristics of Complete Hydatidiform Moles.

Authors:  K B Kubelka-Sabit; I Prodanova; D Jasar; G Bozinovski; V Filipovski; S Drakulevski; D Plaseska-Karanfilska
Journal:  Balkan J Med Genet       Date:  2017-06-30       Impact factor: 0.519

8.  Siglec-6 is expressed in gestational trophoblastic disease and affects proliferation, apoptosis and invasion.

Authors:  Kristen K Rumer; Miriam D Post; Rhea S Larivee; Martina Zink; Jill Uyenishi; Anita Kramer; Deanna Teoh; Kevin Bogart; Virginia D Winn
Journal:  Endocr Relat Cancer       Date:  2012-11-19       Impact factor: 5.678

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.